Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Generate Biomedicines, Inc.NASDAQ: GENB

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash of $160.58M in Q1 FY2026

Q1 FY2026 net change in cash was $160.58M.

Context

  • Net change in cash amounted to 174.9% of revenue in FY2025, down 236.4 pp from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$160.58M— QoQ
Last fiscal yearDec 2025
-$55.79M-33.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-33.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(55.79M) USD
Year-over-year change
+33.7%

Net Change in Cash vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 net change in cash of $55.79M is the largest of the 5 companies compared; the peer median is $43.49M.
  • Its year-over-year change of -33.7% is the 4th highest of 5, against a peer median of +108.2%.
  • Net change in cash amounts to 174.9% of revenue for GENB, versus a peer median of 1502.9%.
GENB Competitors Peer median
Net Change in Cash for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GENBGenerate Biomedicines, Inc.FY2025$55.79M -33.7%—174.9%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$54.86M +52.6%—4220.2%
ABSIAbsci CorporationLTM Mar 2026$54.44M +346.3%-43.2%2964.9%
STROSutro Biopharma, Inc.LTM Mar 2026$32.55M -179.4%—32.7%
ABCLAbCellera Biologics Inc.LTM Sep 2026$27.72M +163.7%-31.0%40.8%
Peer median (excluding GENB) $43.49M+108.2%-37.1%1502.9%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.